US drug giant Pfizer said Thursday it will appeal a Canadian federal court decision paving the way for the pharmaceutical firm Apotex to launch a generic version of its anti-cholesterol drug Lipitor.
The court had previously denied Pfizer's request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of a Pfizer patent in July 2010.
Cholesterol Drug Simvastatin Associated With Sleep Disruptions
New research finds that the cholesterol- lowering drug, simvastatin, can affect the sleeping patterns of some patients.
Advertisement
The drug (atorvastatin calcium) has generated 13 billion dollars in sales worldwide for Pfizer, making it the leading cholesterol-lowering medication.
Lipitor is used to treat high cholesterol, helping to prevent heart disease and hardening of the arteries -- conditions that can lead to heart attack, stroke, and vascular disease.
Pfizer said the Canadian court's decision "has no immediate commercial impact because Lipitor is protected by other patents in Canada, which also are the subject of pending legal challenges."
The ruling by the federal court also has no impact on Lipitor patent litigation in other countries, the company said.
Source: AFP
LIN/M
Advertisement
Pfizer said the Canadian court's decision "has no immediate commercial impact because Lipitor is protected by other patents in Canada, which also are the subject of pending legal challenges."
The ruling by the federal court also has no impact on Lipitor patent litigation in other countries, the company said.
Source: AFP
LIN/M
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial